Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories, a microcap pharmaceutical company, has reached a 52-week high on November 4th, 2024, with its stock currently trading at Rs.94.9, an all-time high. Despite underperforming the sector today and experiencing some volatility, the stock is trading higher than its moving averages, indicating a positive trend. In the past year, the company has shown significant growth compared to the Sensex, showcasing its strong performance in the pharmaceutical industry. Investors are advised to conduct their own research and seek professional advice before making any investment decisions.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs.94.9 on November 4th, 2024. The stock has been outperforming the sector by 2.62% and has been on a consecutive upward trend for the past 6 days, with a 30% increase in returns. It is currently trading above its moving averages and has shown an impressive 1-year performance of 282.57%, showcasing its strong growth potential.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has reported a positive financial performance in the second quarter of fiscal year 2024-2025. Key indicators such as Profit Before Tax, Net Sales, Operating Profit, and Profit After Tax have shown significant improvement, indicating a promising future for the company in the pharmaceutical industry.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs.92.75 on October 7, 2024. The company's consistent performance and positive market sentiment have contributed to this growth, with a 39.6% increase in the past 9 days. It has also outperformed the sector by 2.24% and is currently trading higher than its moving averages, indicating a bullish trend. In the past year, the company has outperformed the Sensex by a significant margin, showcasing its strong fundamentals and potential for future growth.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a significant increase in its share price, reaching an all-time high of Rs. 92.75 on October 7th, 2024. Despite being rated as 'Sell' by MarketsMOJO, the company has outperformed the sector by 2.33% and has been on a consecutive gain for 9 days. Its strong performance and growth potential make it a promising player in the market.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs.88.8 on October 6th, 2024. Despite a 'Sell' rating from MarketsMOJO, the company has outperformed the sector by 3.6% and has been on a consecutive gain for 8 days. Its strong performance and bullish trend make it a promising investment in the pharmaceutical industry.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has been in the spotlight as its stock price reached an all-time high of Rs.88.8 on October 5th, 2024. The company's strong financial performance and consistent growth have led to a 36.3% increase in the past 8 days, outperforming the sector by 3.6%. With a 256.34% growth in the last year, the stock has been trading above its moving averages, indicating a sustained uptrend. While analysts have given it a 'Sell' rating, Gujarat Terce Laboratories has shown potential in the pharmaceutical industry.

Gujarat Terce Laboratories Ltd, a microcap pharmaceutical company, has seen a 35.84% increase in returns for investors in the past 8 days, outperforming the sector by 3.14%. Its stock has reached a 52-week high and is currently trading at Rs.88.8, showing a bullish trend and potential for growth in the pharmaceutical industry.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on October 4th, 2024. It has outperformed its sector by 2.4% and gained for 8 consecutive days, with a significant increase of 35.07% in returns. The stock is currently rated as a 'Sell' by MarketsMOJO.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on October 3rd, 2024. The stock has outperformed its sector by 4.82% and gained 32.29% in the last 7 days. It is currently trading higher than its moving averages and has shown a strong 1-year performance of 233.72%. However, MarketsMOJO has given a 'Sell' call for the stock, so investors should do their own research before making any investment decisions.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has been making headlines in the stock market with its recent all-time high stock price. Despite a 'Sell' call from MarketsMOJO, the stock has outperformed the sector in the past year and is still trading higher than its moving averages. Its potential for growth makes it a company to watch.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high on October 2nd, 2024. The company's stock has been on an upward trend for the past 6 days, with a 26% gain. Despite a 'Sell' call from MarketsMOJO, the company's stock has outperformed the sector and has shown impressive growth in the past year. With a positive trend in its stock price and strong performance, Gujarat Terce Laboratories is a company to watch in the pharmaceutical industry.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on October 1st, 2024. The stock has consistently outperformed the market and is currently rated as 'Sell' by MarketsMOJO. With a 223.87% increase in the past year, the company shows strong potential for growth.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has been making waves in the stock market with its stock price reaching an all-time high of Rs.81.5 on October 1st, 2024. The company's consistent growth and strong financials have led to a 22.95% gain in the past 6 days, outperforming the sector by 2.35%. With a 1-year performance of 224.67%, Gujarat Terce Laboratories has proven to be a top performer in the pharmaceutical industry.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has reached a 52-week high on September 17, 2024. The stock has been performing well, outperforming the sector by 4.85% and seeing a consecutive gain for the last 6 days. It has also shown a 293.50% increase in the past year, indicating strong potential for growth in the industry.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has been making headlines in the stock market with its share price reaching an all-time high of Rs. 78.7 on September 17, 2024. Despite being rated as a 'Sell' by MarketsMOJO, the stock has outperformed the sector by 5% and has been on a consecutive gain streak for the past 6 days. It is currently trading above all its moving averages and has shown an impressive growth of 293.50% in the past year, solidifying its position as a promising player in the industry.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, hitting a 52-week high on September 16, 2024. The stock has consistently outperformed its sector and is currently trading at an all-time high of Rs 75.11. Despite a 'Sell' call from MarketsMOJO, the company's stock has shown impressive growth in the past year.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has gained attention in the stock market with its share price reaching an all-time high of Rs. 75.11 on September 16, 2024. Despite being rated as a 'Sell' by MarketsMOJO, the company has consistently outperformed the sector and has shown a remarkable 23.13% increase in returns in the last 5 days. With a strong and sustained uptrend, Gujarat Terce Laboratories has also outperformed the Sensex in the last year, showcasing its potential for growth and delivering returns to investors.

Gujarat Terce Laboratories, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs. 71.54 on September 15, 2024. Despite a 'Sell' rating from MarketsMOJO, the company has outperformed the sector by 4.95% and has shown consecutive gains in the last four days. It is currently trading higher than its moving averages and has outperformed the Sensex by a remarkable 240.02% in the past year.